Open access · OA
via OpenAlex
Formulation Development and Evaluation of Mouth Dissolving Film of Taurine and Their Future Perspectives
Open Access Journal of Pharmaceutical Research · 2024
Abstract
This study focuses on the formulation development and evaluation of mouth dissolving films (MDFs) containing taurine, an amino acid with potential therapeutic benefits. Taurine-loaded MDFs were formulated using hydroxypropyl methylcellulose (HPMC) E5 as the polymer, polyethylene glycol 400 (PEG 400) as the plasticizer, and sucrose as the sweetening agent. Additional ingredients included menthol for flavoring and citric acid for saliva stabilization. The formulations were evaluated for various parameters including physical appearance, thickness, weight variation, surface pH, in vitro disintegration time, folding endurance, drug content, and in vitro drug release. Results demonstrated uniformity, flexibility, and rapid drug release, with formulation F5 exhibiting the highest drug content and desirable properties. Future perspectives include exploring therapeutic applications, personalized medicine, and regulatory approval for clinical use. This study highlights the potential of taurine MDFs as a patient-friendly dosage form with promising therapeutic efficacy
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.23880/oajpr-16000306
- Canonical
- link ↗
- Fetched
- 2026-11-04 MST
Cite this
APA
RN, A. (2024). Formulation Development and Evaluation of Mouth Dissolving Film of Taurine and Their Future Perspectives. <em>Open Access Journal of Pharmaceutical Research</em>. https://doi.org/10.23880/oajpr-16000306
Vancouver
RN A. Formulation Development and Evaluation of Mouth Dissolving Film of Taurine and Their Future Perspectives. Open Access Journal of Pharmaceutical Research. 2024. doi:10.23880/oajpr-16000306.
BibTeX
@article{ajay2024Formul,
title = {Formulation Development and Evaluation of Mouth Dissolving Film of Taurine and Their Future Perspectives},
author = {Ajay RN},
journal = {Open Access Journal of Pharmaceutical Research},
year = {2024},
doi = {10.23880/oajpr-16000306},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Molecular Neurodegeneration 2014
Open access · CC-BY
Alpha-synuclein and tau: teammates in neurodegeneration?
Cellular and Molecular Immunology 2023
Preprint · OA
Taurine as a possible therapy for immunosenescence and inflammaging
Antioxidants 2023
Open access · CC-BY
Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management
Nanotheranostics 2025
Open access · CC-BY
Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine
Molecular medicine reports 2026
Open access · OA
SIRT1/AMPK/PGC1α pathway in ischemic stroke: Elucidating neuroprotective strategies (Review).
Philosophical Transactions of the Royal Society B Biological Sciences 2026
Open access · CC-BY